Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 20/20 | 1.00 |
| ▸ | F13A1 | P00488 | 2/20 | 0.69 |
| ▸ | TGM1 | P22735 | 2/20 | 0.69 |
| ▸ | TGM6 | O95932 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19480311 | 1.00 | TGM2 (1.00) | TGM2F13A1TGM1TGM6 | |
| SCHEMBL22895154 | 0.91 | TGM2 (1.00) | TGM2F13A1TGM1TGM6 | |
| SCHEMBL15619631 | 0.89 | TGM2 (1.00) | TGM2F13A1TGM1TGM6 | |
| SCHEMBL31032996 | 0.88 | TGM2 (0.95) | TGM2F13A1TGM1TGM6 | |
| SCHEMBL19464180 | 0.88 | TGM2 (1.00) | TGM2F13A1TGM1TGM6 | |
| SCHEMBL19480306 | 0.86 | TGM2 (1.00) | TGM2 | |
| SCHEMBL31033030 | 0.86 | TGM2 (1.00) | TGM2 | |
| SCHEMBL31033018 | 0.86 | TGM2 (1.00) | TGM2F13A1TGM1TGM6 | |
| SCHEMBL22895108 | 0.86 | TGM2 (1.00) | TGM2F13A1TGM1TGM6 | |
| SCHEMBL17007552 | 0.86 | TGM2 (0.83) | TGM2F13A1TGM1TGM6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 974 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131009-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4725957-A1 | GROUP OF CYCLIC ALKALINE LIPOPEPTIDE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2026-04-15 | — | — | EP | claimed |
| US-20260100856-A1 | DYNAMIC SMART CONTRACT SECURITY AND VERIFICATION SYSTEM USING CAPSULE NETWORKS, AUTOENCODERS, AND GENERATIVE ADVERSARIAL NETWORKS | LEPTUDE INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12597780-B2 | Semi-autonomous electric power generation system and operation method thereof | ECOGENSELF, S.A. DE C.V. (MX) | 2026-04-07 | — | — | US | claimed |
| US-20260085103-A1 | LONG-ACTING INSULIN COMPOUND | CHENGDU AODA BIOTECHNOLOGY CO LTD (CN) | 2026-03-26 | — | — | US | claimed |
| WO-2026040845-A1 | FUSED ADENO-ASSOCIATED VIRUS CAPSID PROTEIN, ADENO-ASSOCIATED VIRUS AND USE THEREOF | 上海玮美基因科技有限责任公司 | 2026-02-26 | — | — | WO | claimed |
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES, LLC (US) | 2026-02-17 | — | — | US | claimed |
| US-20260010773-A1 | TEMPORAL DYNAMICS SIMULATION IN MATMUL-FREE NEURAL ARCHITECTURES | LEPTUDE INC (US) | 2026-01-08 | — | — | US | claimed |
| EP-4673424-A1 | LIQUID PHASE PEPTIDE SUPPORT SYNTHESIS OF PEPTIDES AND PEPTIDOMIMETICS | Regeneron Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| US-12496350-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | OHIO STATE INNOVATION FOUNDATION (US) | 2025-12-16 | — | — | US | claimed |
| CN-114249802-A | Coronavirus antagonistic peptide and application thereof | 常州文松生物技术有限公司 | 2022-03-29 | — | — | CN | claimed |
| US-11261237-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | NORTHWESTERN UNIVERSITY (US) | 2022-03-01 | — | — | US | claimed |
| WO-2022037469-A1 | LONG-ACTING RELAXIN-2 ANALOG | 成都奥达生物科技有限公司 | 2022-02-24 | — | — | WO | claimed |
| WO-2022037470-A2 | LONG-ACTING INSULIN ANALOG | 成都奥达生物科技有限公司 | 2022-02-24 | — | — | WO | claimed |
| CN-114075276-A | Long-acting relaxin 2 analogue | 成都奥达生物科技有限公司 | 2022-02-22 | — | — | CN | claimed |
| CN-114080394-A | Novel theta-defensin analogs | 迈克尔·E·塞尔斯特德 | 2022-02-22 | — | — | CN | claimed |
| CN-114075275-A | Long-acting insulin analogue | 成都奥达生物科技有限公司 | 2022-02-22 | — | — | CN | claimed |
| CN-114072415-A | Compositions and methods for treating fungal infections | 迈克尔·E·塞尔斯特德 | 2022-02-18 | — | — | CN | claimed |
| WO-2022023723-A1 | GLP-1 RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-02-03 | — | — | WO | claimed |
| WO-2022026463-A1 | OXYTOCIN ANALOGUES AND METHODS FOR USING THE SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085103-A1 | LONG-ACTING INSULIN COMPOUND | IAPP, INSR, IDE | TGM2 621/4885F13A1 211/4885TGM1 524/4885 |
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, INSR | TGM2 653/4885F13A1 2103/4885TGM1 1583/4885 |
| US-20260010773-A1 | TEMPORAL DYNAMICS SIMULATION IN MATMUL-FREE NEURAL ARCHITECTURES | NES, NCSTN, CHAT | TGM2 3259/4885F13A1 4453/4885TGM1 3751/4885 |
| US-12597780-B2 | Semi-autonomous electric power generation system and operation method thereof | SCO2, TAOK1, RRS1 | TGM2 3642/4885F13A1 3765/4885TGM1 2948/4885 |
| US-20260100856-A1 | DYNAMIC SMART CONTRACT SECURITY AND VERIFICATION SYSTEM USING CAPSULE NETWORKS, AUTOENCODERS, AND GENERATIVE ADVERSARIAL NETWORKS | NCSTN, LBR, SMARCD2 | TGM2 1796/4885F13A1 2453/4885TGM1 1676/4885 |
| US-20260131009-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | PIK3R5, PIK3R4, PIK3R1 | TGM2 2779/4885F13A1 4694/4885TGM1 3822/4885 |
| US-11261237-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | VEGFA, LITAF, FIBP | TGM2 3090/4885F13A1 384/4885TGM1 3737/4885 |
| US-12496350-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | CNBP, CALU, CLSPN | TGM2 3313/4885F13A1 780/4885TGM1 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.